Entrada Therapeutics (TRDA) Shares Outstanding (Weighted Average) (2020 - 2026)

Entrada Therapeutics' Shares Outstanding (Weighted Average) history runs 7 years deep, the most recent figure standing at $41.8 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 1.86% year-over-year to $41.8 million; the TTM figure through Mar 2026 stood at $41.8 million (up 1.86% YoY), while the FY2025 annual figure was $41.4 million, up 10.9% from the prior year.
• Shares Outstanding (Weighted Average) was $41.8 million for Q1 2026 at Entrada Therapeutics, up from $41.4 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $41.8 million in Q1 2026 to a low of $31.2 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $35.5 million across 5 years, with a median of $33.5 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Shares Outstanding (Weighted Average) surged 2386.85% in 2022, then advanced 1.86% in 2026.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $31.3 million in 2022, then climbed by 5.61% to $33.1 million in 2023, then climbed by 12.88% to $37.3 million in 2024, then advanced by 10.9% to $41.4 million in 2025, then rose by 1.12% to $41.8 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $41.8 million (Q1 2026), $41.4 million (Q4 2025), and $41.5 million (Q3 2025), per Business Quant data.